The presence of aPL's (aCL IgG, aPT IgG) and APS did not predict any of the clinical or angiographic outcomes in the study including markers of atherosclerotic and thrombotic burden. This evidence concerns the gene LYPLA2P1 and autoimmune polyendocrinopathy.